<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041756</url>
  </required_header>
  <id_info>
    <org_study_id>2001065</org_study_id>
    <nct_id>NCT00041756</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis</brief_title>
  <official_title>Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Procter and Gamble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742
      inhibits some MMPs, potentially limiting cartilage degradation and disease progression. This
      study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate
      knee osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Matrix metalloproteinases have been implicated in the cartilage degradation that occurs in
      osteoarthritis. PG-530742 inhibits some of these matrix metalloproteinases, thus potentially
      limiting cartilage degradation and disease progression. This study will test the efficacy and
      safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Minimum Joint Space Width in the Medial Compartment of the Tibiofemoral Joint of the Signal Knee After 1 Year of Treatment</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>The structural primary efficacy endpoint is the 1-year change from baseline in minimum joint space width (JSW) in the medial compartment of the tibiofemoral joint of the signal knee, as measured by microfocal knee radiographs obtained in the semi-flexed position.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 1 Year</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>The symptomatic primary efficacy endpoint is the change in total WOMAC scores after 1 year of treatment. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items), Stiffness (2 items), Physical Function (17 items). The WOMAC uses descriptors for all items: none, mild moderate, severe, and extreme (corresponding to an ordinal scale of 0-4.) Scores are summed for items in each subscale, with possible ranges as follows: pain=0-20, stiffness=0-8, physical function=0-68. The total WOMAC score is created by summing the items for all three subscales (min=0, max=96)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg PG-530742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg PG-530742</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg PG-530742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg PG-530742</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg PG-530742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg PG-530742</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg PG-530742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg PG-530742</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PG-530742</intervention_name>
    <description>One 25 mg PG-530742 tablet, twice daily for for one year</description>
    <arm_group_label>25 mg PG-530742</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One placebo tablet, twice daily for for one year</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg PG-530742</intervention_name>
    <description>One 50 mg PG-530742 tablet, twice daily for for one year</description>
    <arm_group_label>50 mg PG-530742</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg PG-530742</intervention_name>
    <description>100 mg PG-530742 tablet, twice a day for one year</description>
    <arm_group_label>100 mg PG-530742</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg PG-530742</intervention_name>
    <description>200 mg PG-530742 tablet, twice a day for one year</description>
    <arm_group_label>200 mg PG-530742</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild to moderate knee osteoarthritis confirmed by a radiographic technique.

        Exclusion Criteria:

          -  secondary knee osteoarthritis;

          -  diseases other than osteoarthritis that could cause knee pain;

          -  any disease or intervention (surgery, intra-articular injection) that would have an
             impact on knee pain or mobility;

          -  drugs that act potentially on the bone or cartilage component of the knee joint.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Beary, MD</last_name>
    <role>Study Director</role>
    <affiliation>Procter and Gamble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rehabilitation Hospital, Gizella telep</name>
      <address>
        <city>Visegrad</city>
        <state>Gizella telep</state>
        <zip>2026</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz A. Country Hospital, Department of Rheumatology, Hid utca 2.</name>
      <address>
        <city>Gyor</city>
        <state>Hid Utica 2</state>
        <zip>9025</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Rheumatology and Physiotherapy, Dept. of Rheumatology and Immunology, Frankel Leo u. 38-40</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Rheumatology and Physiotherapy, Dept. of Rheumatology I and Metabolic Osteology, Frankel Leo u. 38-40</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Rheumatology and Physiotherapy, Dept. of Rheumatology IV., Frankel Leo u. 38-40</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Clinic, Karolina ut 17</name>
      <address>
        <city>Budapest</city>
        <zip>1113</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Ferenc Hospital, Department of Rheumatology, Csabai Kapu 42.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>95 Stanwell Road</name>
      <address>
        <city>Ashford</city>
        <state>Middlesex</state>
        <zip>TW15 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal National Orthapaedic Hsopital, Brackley Hill</name>
      <address>
        <city>Stanmore</city>
        <state>Middlesex</state>
        <zip>HA 7 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Thomas Hospital, Lambeth Place Road</name>
      <address>
        <city>London</city>
        <state>Se17eh</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Crouch Oak Practice, 45 Station Road, Addlestone</name>
      <address>
        <city>Addlestone</city>
        <state>Surrey</state>
        <zip>KT15 2BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Centre, Kingston Avenue</name>
      <address>
        <city>East Horsley</city>
        <state>Surrey</state>
        <zip>KT24 6QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridge House Medical Centre, Scholars Lane</name>
      <address>
        <city>Stratford-upon-avon</city>
        <state>Warwickshire</state>
        <zip>CV37 6HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pound Hill Surgery, 1 Crawley Lane, Pound Hill</name>
      <address>
        <city>Crawley</city>
        <state>West Sussex</state>
        <zip>RH10 7DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Rheumatology Selly Oak Hospital, Raddleburn Road, Selly Oak</name>
      <address>
        <city>Birmingham</city>
        <zip>B29 6JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Birmingham Clinical Research Centre, Birmingham Research Park</name>
      <address>
        <city>Edgbaston</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grosvenor Medical Centre Clinical Trials Unit, 18 upper Grosvenor Road, Tunbridge Wells</name>
      <address>
        <city>Kent</city>
        <zip>TN 1 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department, Fourth Floor, Thomas Guy House, St Guy's House</name>
      <address>
        <city>London Bridge</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Rheumatology Whipps Cross University Hospital, Whipps Cross Road</name>
      <address>
        <city>London</city>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Rheumatology Dulwich Hospital, East Dulwich</name>
      <address>
        <city>London</city>
        <zip>SE22 8PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Reading Clinical Research Centre, Whiteley Glebe, 11 Glebe Road, off Christchurch Gardens</name>
      <address>
        <city>Reading</city>
        <zip>RG2 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hildenborough Medical Group, Trenchwood Surgery, 264 Shipbourne Road</name>
      <address>
        <city>Tonbridge</city>
        <zip>TN10 3ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Wrightington, Wrightington Hospital, Hall Lane, Awpley Bridge</name>
      <address>
        <city>Wigan</city>
        <zip>WN6 9EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2002</study_first_submitted>
  <study_first_submitted_qc>July 16, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2002</study_first_posted>
  <results_first_submitted>August 3, 2011</results_first_submitted>
  <results_first_submitted_qc>November 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2011</results_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Disease: Knee Primary Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Tablet</title>
          <description>Placebo tablet dosed BID</description>
        </group>
        <group group_id="P2">
          <title>25 mg PG-530742</title>
          <description>25 mg PG-530742 dosed BID</description>
        </group>
        <group group_id="P3">
          <title>50 mg PG-530742</title>
          <description>50 mg PG-530742 dosed BID</description>
        </group>
        <group group_id="P4">
          <title>100 mg PG-530742</title>
          <description>100 mg PG-530742 dosed BID</description>
        </group>
        <group group_id="P5">
          <title>200 mg PG-530742</title>
          <description>200 mg PG-530742 dosed BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to meet protocol criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Data Monitoring Committee Recommendation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Tablet</title>
          <description>Placebo tablet dosed BID</description>
        </group>
        <group group_id="B2">
          <title>25 mg PG-530742</title>
          <description>25 mg PG-530742 dosed BID</description>
        </group>
        <group group_id="B3">
          <title>50 mg PG-530742</title>
          <description>50 mg PG-530742 dosed BID</description>
        </group>
        <group group_id="B4">
          <title>100 mg PG-530742</title>
          <description>100 mg PG-530742 dosed BID</description>
        </group>
        <group group_id="B5">
          <title>200 mg PG-530742</title>
          <description>200 mg PG-530742 dosed BID</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="79"/>
            <count group_id="B4" value="80"/>
            <count group_id="B5" value="79"/>
            <count group_id="B6" value="395"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" spread="0.92"/>
                    <measurement group_id="B2" value="62.4" spread="0.86"/>
                    <measurement group_id="B3" value="62.6" spread="0.92"/>
                    <measurement group_id="B4" value="62.9" spread="0.95"/>
                    <measurement group_id="B5" value="63.1" spread="0.80"/>
                    <measurement group_id="B6" value="62.6" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="76"/>
                    <measurement group_id="B6" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Minimum Joint Space Width in the Medial Compartment of the Tibiofemoral Joint of the Signal Knee After 1 Year of Treatment</title>
        <description>The structural primary efficacy endpoint is the 1-year change from baseline in minimum joint space width (JSW) in the medial compartment of the tibiofemoral joint of the signal knee, as measured by microfocal knee radiographs obtained in the semi-flexed position.</description>
        <time_frame>baseline and 12 months</time_frame>
        <population>An intent-to-treat (ITT) analysis was conducted on all patients who were randomized and took at least one dose of study drug. Any missing data for these patients was not imputed in the primary analysis.
analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Tablet</title>
            <description>Placebo tablet dosed BID</description>
          </group>
          <group group_id="O2">
            <title>25 mg PG-530742</title>
            <description>25 mg PG-530742 dosed BID</description>
          </group>
          <group group_id="O3">
            <title>50 mg PG-530742</title>
            <description>50 mg PG-530742 dosed BID</description>
          </group>
          <group group_id="O4">
            <title>100 mg PG-530742</title>
            <description>100 mg PG-530742 dosed BID</description>
          </group>
          <group group_id="O5">
            <title>200 mg PG-530742</title>
            <description>200 mg PG-530742 dosed BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Minimum Joint Space Width in the Medial Compartment of the Tibiofemoral Joint of the Signal Knee After 1 Year of Treatment</title>
          <description>The structural primary efficacy endpoint is the 1-year change from baseline in minimum joint space width (JSW) in the medial compartment of the tibiofemoral joint of the signal knee, as measured by microfocal knee radiographs obtained in the semi-flexed position.</description>
          <population>An intent-to-treat (ITT) analysis was conducted on all patients who were randomized and took at least one dose of study drug. Any missing data for these patients was not imputed in the primary analysis.
analysis.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1361" spread="0.0627"/>
                    <measurement group_id="O2" value="-0.0442" spread="0.0624"/>
                    <measurement group_id="O3" value="-0.2261" spread="0.0650"/>
                    <measurement group_id="O4" value="-0.2000" spread="0.0650"/>
                    <measurement group_id="O5" value="-0.1916" spread="0.0723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 1 Year</title>
        <description>The symptomatic primary efficacy endpoint is the change in total WOMAC scores after 1 year of treatment. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items), Stiffness (2 items), Physical Function (17 items). The WOMAC uses descriptors for all items: none, mild moderate, severe, and extreme (corresponding to an ordinal scale of 0-4.) Scores are summed for items in each subscale, with possible ranges as follows: pain=0-20, stiffness=0-8, physical function=0-68. The total WOMAC score is created by summing the items for all three subscales (min=0, max=96)</description>
        <time_frame>baseline and 12 months</time_frame>
        <population>An intent-to-treat (ITT) analysis was conducted on all patients who were randomized and took at least one dose of study drug. Any missing data for these patients was not imputed in the primary analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Tablet</title>
            <description>Placebo tablet dosed BID</description>
          </group>
          <group group_id="O2">
            <title>25 mg PG-530742</title>
            <description>25 mg PG-530742 dosed BID</description>
          </group>
          <group group_id="O3">
            <title>50 mg PG-530742</title>
            <description>50 mg PG-530742 dosed BID</description>
          </group>
          <group group_id="O4">
            <title>100 mg PG-530742</title>
            <description>100 mg PG-530742 dosed BID</description>
          </group>
          <group group_id="O5">
            <title>200 mg PG-530742</title>
            <description>200 mg PG-530742 dosed BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 1 Year</title>
          <description>The symptomatic primary efficacy endpoint is the change in total WOMAC scores after 1 year of treatment. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items), Stiffness (2 items), Physical Function (17 items). The WOMAC uses descriptors for all items: none, mild moderate, severe, and extreme (corresponding to an ordinal scale of 0-4.) Scores are summed for items in each subscale, with possible ranges as follows: pain=0-20, stiffness=0-8, physical function=0-68. The total WOMAC score is created by summing the items for all three subscales (min=0, max=96)</description>
          <population>An intent-to-treat (ITT) analysis was conducted on all patients who were randomized and took at least one dose of study drug. Any missing data for these patients was not imputed in the primary analysis.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="2.81"/>
                    <measurement group_id="O2" value="-6.7" spread="2.78"/>
                    <measurement group_id="O3" value="-10.0" spread="2.88"/>
                    <measurement group_id="O4" value="-5.8" spread="2.92"/>
                    <measurement group_id="O5" value="-9.3" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Tablet</title>
          <description>Placebo tablet dosed BID</description>
        </group>
        <group group_id="E2">
          <title>25 mg PG-530742</title>
          <description>25 mg PG-530742 dosed BID</description>
        </group>
        <group group_id="E3">
          <title>50 mg PG-530742</title>
          <description>50 mg PG-530742 dosed BID</description>
        </group>
        <group group_id="E4">
          <title>100 mg PG-530742</title>
          <description>100 mg PG-530742 dosed BID</description>
        </group>
        <group group_id="E5">
          <title>200 mg PG-530742</title>
          <description>200 mg PG-530742 dosed BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Biopsy lymph gland abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Cardiac failure NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Atioventricular block NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Tachycardia NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Cataract unilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Duodenal erosions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Gastric erosions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Athralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Localised Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Arthritis NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Periostitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Toe deformities NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Intervertebral disc herniation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fibrositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Spondylosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Ovarian cancer NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urethral stricture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fibrosis NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vertegrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Haemorrhage NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypertension NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders (Overall)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders (Overall)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders (Overall)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders (Overall)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders (Overall)</sub_title>
                <counts group_id="E1" events="31" subjects_affected="14" subjects_at_risk="77"/>
                <counts group_id="E2" events="21" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E3" events="25" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E4" events="34" subjects_affected="16" subjects_at_risk="80"/>
                <counts group_id="E5" events="37" subjects_affected="19" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions (Overall)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E5" events="20" subjects_affected="19" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestation (Overall)</sub_title>
                <counts group_id="E1" events="37" subjects_affected="22" subjects_at_risk="77"/>
                <counts group_id="E2" events="40" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E4" events="35" subjects_affected="24" subjects_at_risk="80"/>
                <counts group_id="E5" events="22" subjects_affected="16" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications (Overall)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations (Overall)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E2" events="31" subjects_affected="16" subjects_at_risk="80"/>
                <counts group_id="E3" events="19" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E4" events="16" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E5" events="23" subjects_affected="10" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders (Overall)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders (Overall)</sub_title>
                <counts group_id="E1" events="91" subjects_affected="37" subjects_at_risk="77"/>
                <counts group_id="E2" events="104" subjects_affected="41" subjects_at_risk="80"/>
                <counts group_id="E3" events="85" subjects_affected="34" subjects_at_risk="79"/>
                <counts group_id="E4" events="135" subjects_affected="43" subjects_at_risk="80"/>
                <counts group_id="E5" events="154" subjects_affected="44" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (Overall)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders (Overall)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E5" events="10" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E4" events="13" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders (Overall)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Thomas</name_or_title>
      <organization>Procter &amp; Gamble</organization>
      <phone>513.622.4838</phone>
      <email>thomas.pr@pg.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

